Canada markets closed

Affimed N.V. (AFMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.6609-0.0408 (-5.81%)
At close: 04:00PM EDT
0.6780 +0.02 (+2.59%)
After hours: 06:14PM EDT
Full screen
Loading interactive chart...
  • Zacks

    Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates

    Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Affimed Reports 2022 Financial Results and Operational Progress

    AFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meetingAFM24: Data from the three ongoing studies expected to be presented at scientific conferences in Q2 or Q3 of 2023AFM28: Clinical phase 1 study is open and recruiting; clinical trial applications now approved in four European countries including Belgium, France, Denmark and SpainAnticipated cash runway into

  • GlobeNewswire

    Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023

    HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “